vs
Side-by-side financial comparison of Arbutus Biopharma Corp (ABUS) and Richmond Mutual Bancorporation, Inc. (RMBI). Click either name above to swap in a different company.
Richmond Mutual Bancorporation, Inc. is the larger business by last-quarter revenue ($13.1M vs $10.7M, roughly 1.2× Arbutus Biopharma Corp). Richmond Mutual Bancorporation, Inc. runs the higher net margin — 26.1% vs 23.5%, a 2.6% gap on every dollar of revenue. On growth, Arbutus Biopharma Corp posted the faster year-over-year revenue change (522.2% vs 18.1%). Over the past eight quarters, Richmond Mutual Bancorporation, Inc.'s revenue compounded faster (9.1% CAGR vs -13.2%).
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
Richmond Mutual Bancorporation, Inc. is a U.S.-based bank holding company operating primarily in Indiana. It offers a full range of personal and commercial banking solutions including deposit accounts, mortgage loans, small business lending, and wealth management services, serving local retail consumers and small-to-medium enterprise clients via its regional branch network.
ABUS vs RMBI — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $10.7M | $13.1M |
| Net Profit | $2.5M | $3.4M |
| Gross Margin | — | — |
| Operating Margin | 13.9% | — |
| Net Margin | 23.5% | 26.1% |
| Revenue YoY | 522.2% | 18.1% |
| Net Profit YoY | 112.7% | 37.7% |
| EPS (diluted) | $0.01 | $0.35 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $13.1M | ||
| Q3 25 | — | $12.6M | ||
| Q2 25 | $10.7M | $11.8M | ||
| Q1 25 | — | $11.4M | ||
| Q4 24 | — | $11.1M | ||
| Q3 24 | — | $10.8M | ||
| Q2 24 | — | $10.7M | ||
| Q1 24 | — | $11.0M |
| Q4 25 | — | $3.4M | ||
| Q3 25 | — | $3.6M | ||
| Q2 25 | $2.5M | $2.6M | ||
| Q1 25 | — | $2.0M | ||
| Q4 24 | — | $2.5M | ||
| Q3 24 | — | $2.5M | ||
| Q2 24 | — | $2.1M | ||
| Q1 24 | — | $2.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 13.9% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 26.1% | ||
| Q3 25 | — | 28.6% | ||
| Q2 25 | 23.5% | 22.0% | ||
| Q1 25 | — | 17.2% | ||
| Q4 24 | — | 22.4% | ||
| Q3 24 | — | 23.0% | ||
| Q2 24 | — | 19.3% | ||
| Q1 24 | — | 21.6% |
| Q4 25 | — | $0.35 | ||
| Q3 25 | — | $0.36 | ||
| Q2 25 | $0.01 | $0.26 | ||
| Q1 25 | — | $0.20 | ||
| Q4 24 | — | $0.25 | ||
| Q3 24 | — | $0.24 | ||
| Q2 24 | — | $0.20 | ||
| Q1 24 | — | $0.23 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $37.4M | $33.1M |
| Total DebtLower is stronger | $0 | — |
| Stockholders' EquityBook value | $83.0M | $145.8M |
| Total Assets | $103.3M | $1.5B |
| Debt / EquityLower = less leverage | 0.00× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $33.1M | ||
| Q3 25 | — | $34.3M | ||
| Q2 25 | $37.4M | $27.2M | ||
| Q1 25 | — | $27.0M | ||
| Q4 24 | — | $21.8M | ||
| Q3 24 | — | $19.6M | ||
| Q2 24 | — | $19.0M | ||
| Q1 24 | — | $20.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $0 | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $145.8M | ||
| Q3 25 | — | $140.0M | ||
| Q2 25 | $83.0M | $132.3M | ||
| Q1 25 | — | $130.9M | ||
| Q4 24 | — | $132.9M | ||
| Q3 24 | — | $140.0M | ||
| Q2 24 | — | $131.1M | ||
| Q1 24 | — | $132.4M |
| Q4 25 | — | $1.5B | ||
| Q3 25 | — | $1.5B | ||
| Q2 25 | $103.3M | $1.5B | ||
| Q1 25 | — | $1.5B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | $1.5B | ||
| Q2 24 | — | $1.5B | ||
| Q1 24 | — | $1.5B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.7M | $16.0M |
| Free Cash FlowOCF − Capex | — | $14.6M |
| FCF MarginFCF / Revenue | — | 111.9% |
| Capex IntensityCapex / Revenue | 0.0% | 10.4% |
| Cash ConversionOCF / Net Profit | -6.24× | 4.68× |
| TTM Free Cash FlowTrailing 4 quarters | — | $26.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $16.0M | ||
| Q3 25 | — | $6.3M | ||
| Q2 25 | $-15.7M | $4.8M | ||
| Q1 25 | — | $2.2M | ||
| Q4 24 | — | $14.8M | ||
| Q3 24 | — | $2.9M | ||
| Q2 24 | — | $2.9M | ||
| Q1 24 | — | $2.2M |
| Q4 25 | — | $14.6M | ||
| Q3 25 | — | $5.8M | ||
| Q2 25 | — | $4.2M | ||
| Q1 25 | — | $2.1M | ||
| Q4 24 | — | $14.3M | ||
| Q3 24 | — | $2.8M | ||
| Q2 24 | — | $2.8M | ||
| Q1 24 | — | $2.0M |
| Q4 25 | — | 111.9% | ||
| Q3 25 | — | 46.2% | ||
| Q2 25 | — | 35.6% | ||
| Q1 25 | — | 18.4% | ||
| Q4 24 | — | 129.3% | ||
| Q3 24 | — | 25.7% | ||
| Q2 24 | — | 26.2% | ||
| Q1 24 | — | 18.7% |
| Q4 25 | — | 10.4% | ||
| Q3 25 | — | 3.7% | ||
| Q2 25 | 0.0% | 5.3% | ||
| Q1 25 | — | 0.7% | ||
| Q4 24 | — | 4.2% | ||
| Q3 24 | — | 1.1% | ||
| Q2 24 | — | 1.1% | ||
| Q1 24 | — | 1.1% |
| Q4 25 | — | 4.68× | ||
| Q3 25 | — | 1.75× | ||
| Q2 25 | -6.24× | 1.86× | ||
| Q1 25 | — | 1.11× | ||
| Q4 24 | — | 5.96× | ||
| Q3 24 | — | 1.17× | ||
| Q2 24 | — | 1.42× | ||
| Q1 24 | — | 0.91× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
